ACE-031
ActRIIB–IgG1 Fc fusion — development discontinued; no monomer CID; refuse PE glow.
Editorial review:Evidence snapshot
This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.
Identity lock. ACE-031 (also discussed as a soluble activin type IIB receptor–IgG1 Fc fusion / ActRIIB-Fc class agent; sometimes named in development narratives alongside ramatercept-class framing) is a fusion protein, not a short peptide monomer. No clean PubChem small-molecule CID is locked in this pack (expected for a recombinant Fc fusion). It was developed to bind myostatin / activin ligands and increase muscle mass. Clinical development stopped after safety signals (including epistaxis / telangiectasia narratives) in the Duchenne program. Black-market ACE-031 detections appear in anti-doping literature — detecting a seized vial ≠ clinical efficacy. No approved indication. Off-label does not apply. There is no label to be off of. Refuse physique / performance-enhancement glow. This drawer marks papers. It is not use advice.
Bottom line
Human data include a single ascending-dose healthy-volunteer study and a randomized placebo-controlled trial in ambulatory boys with Duchenne muscular dystrophy that did not become an approved therapy. Preclinical ActRIIB-Fc muscle-growth papers (mouse, marmoset) are not human grades. Refuse bodybuilding / “myostatin blocker” glow from this set.
Papers
Human clinical (development stopped)
PMID 23169607 — Attie 2013
Tested: single ascending-dose study of ACE-031 in healthy volunteers (pharmacodynamic muscle/biomarker framing).
Does not show: an approved indication, long-term safety in athletes, or that gray-market vials match trial material.
PMID 27462804 — Campbell 2017
Tested: randomized, placebo-controlled clinical trial of ACE-031 in ambulatory boys with Duchenne muscular dystrophy.
Does not show: a marketed DMD therapy; development was discontinued amid safety concerns — trial result ≠ consumer use claim.
Preclinical ActRIIB-Fc / muscle mass (not human grades)
PMID 20466801 — Cadena 2010
Tested: soluble activin type IIB receptor administration promoting skeletal muscle growth independent of fiber type (rodent framing).
Does not show: human hypertrophy efficacy or safety for unlabeled use.
PMID 41256654 — Cadena 2025
Tested: ACE-031 increasing muscle mass and strength in the common marmoset.
Does not show: a human body-composition RCT or approved sports indication.
Detection / anti-doping context (identity ≠ efficacy)
PMID 40312924 — Reichel 2025
Tested: gel electrophoretic detection methods for black-market ACE-031.
Does not show: clinical benefit; analytical detection of illicit product is not an efficacy grade.
PMID 26842585 — Thevis 2016
Tested: review of emerging drugs affecting skeletal muscle function / mitochondrial biogenesis and sports drug-testing implications (includes myostatin-pathway agents in class discussion).
Does not show: ACE-031 human therapeutic approval.
What is not established
Any approved human indication for ACE-031. That preclinical muscle mass increases equal safe human performance enhancement. Equivalence of unlabeled “ACE-031” research chemicals to clinical-batch ActRIIB-Fc. A PubChem monomer CID for this fusion protein. This drawer does not provide use advice, schedules, or sourcing.
Selected sources
Reported experiences
Reported topics are not established benefits.Risks and unknowns
Compare experiences with care.
Join the discussion
Verified members can contribute to compound conversations.